MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530027 | Name: Acreozast

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Acreozast is a histamine release inhibitor potentially for the treatment of asthma and atopic dermatitis.

Chemical Structure

Acreozast
CAS#123548-56-1

Theoretical Analysis

MedKoo Cat#: 530027

Name: Acreozast

CAS#: 123548-56-1

Chemical Formula: C15H14ClN3O6

Exact Mass: 367.0600

Molecular Weight: 367.74

Elemental Analysis: C, 48.99; H, 3.84; Cl, 9.64; N, 11.43; O, 26.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
TYB-2285; TYB2285; TYB 2285
IUPAC/Chemical Name
((2-chloro-5-cyano-1,3-phenylene)bis(azanediyl))bis(2-oxoethane-2,1-diyl) diacetate
InChi Key
VNVBCWREJHKWSG-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H14ClN3O6/c1-8(20)24-6-13(22)18-11-3-10(5-17)4-12(15(11)16)19-14(23)7-25-9(2)21/h3-4H,6-7H2,1-2H3,(H,18,22)(H,19,23)
SMILES Code
N#CC1=CC(NC(COC(C)=O)=O)=C(Cl)C(NC(COC(C)=O)=O)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 367.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tohda Y, Muraki M, Kubo H, Nakajima S, Fukuoka M, Watanabe A. Effect of TYB-2285 on early and late bronchial responses and airway hyperreactivity in actively sensitized guinea pigs. Gen Pharmacol. 1998 Aug;31(2):323-8. PubMed PMID: 9688481. 2: Abraham WM, Ahmed A, Cortes A, Sielczak M, Wantanabe A. Effect of TYB-2285 on antigen-induced airway responses in sheep. Pulm Pharmacol. 1996 Feb;9(1):49-58. PubMed PMID: 8843510. 3: Watanabe A, Tominaga T, Shutoh H, Hayashi H, Tsuji J. Effect of TYB-2285 on peritoneal anaphylaxis in passively sensitized rats. Gen Pharmacol. 1998 Aug;31(2):313-7. PubMed PMID: 9688479. 4: Tominaga T, Watanbe A, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effect of TYB-2285 on antigen-induced accumulation of eosinophils into the peritoneal cavity of rats sensitized with Ascaris suum extract. Gen Pharmacol. 1997 Mar;28(3):411-4. PubMed PMID: 9068982. 5: Watanabe A, Tominaga T, Shutoh H, Hayashi H, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effect of TYB-2285 on lung anaphylaxis in actively sensitized rats. Gen Pharmacol. 1997 Feb;28(2):305-9. PubMed PMID: 9013209. 6: Tominaga T, Watanabe A, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. The effects of TYB-2285 and its metabolites on lymphocyte responses in vitro. Gen Pharmacol. 1997 Sep;29(3):473-5. PubMed PMID: 9378259. 7: Kou K, Hayashi M, Nakajima T, Yoshizawa I, Kawano Y, Shikishima Y, Noma T. [Immunomodulation by TYB-2285 of Dermatophagoides farinae (Df) antigen-induced IFN-gamma and IL-4 production in lymphocytes from children with bronchial asthma]. Arerugi. 1997 Jun;46(6):502-10. Japanese. PubMed PMID: 9277001. 8: Watanabe A, Tominaga T, Shutoh H, Hayashi H, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effect of TYB-2285 on passive cutaneous anaphylaxis in rats. Gen Pharmacol. 1997 Feb;28(2):311-5. PubMed PMID: 9013210. 9: Tominaga T, Watanabe A, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effects of TYB-2285 on the accumulation of eosinophils in the airway induced by antigen exposure in actively sensitized brown Norway rats. Gen Pharmacol. 1997 Feb;28(2):301-3. PubMed PMID: 9013208. 10: Ban M, Taguchi H, Katsushima T, Takahashi M, Shinoda K, Watanabe A, Tominaga T. Novel antiallergic and antiinflammatory agents. Part II: Synthesis and pharmacology of TYB-2285 and its related compounds. Bioorg Med Chem. 1998 Jul;6(7):1077-87. PubMed PMID: 9730245. 11: Muraki M, Tohda Y, Sugihara R, Nagasaka Y, Nakajima S. The effect of TYB-2285 on dual phase bronchoconstriction and airway hypersensitivity in guinea-pigs actively sensitized with ovalbumin. J Pharm Pharmacol. 1994 Nov;46(11):883-6. PubMed PMID: 7897592. 12: Tominaga T, Watanabe A, Hayashi H, Yanagihara Y, Koda A. Effect of TYB-2285 on histamine release from human basophils in the presence/absence of IL-3. Gen Pharmacol. 1993 Mar;24(2):345-8. PubMed PMID: 7683300. 13: Watanabe A, Tominaga T, Hayashi H, Yanagihara Y, Koda A. Effect of TYB-2285 on antigen-induced histamine release from mouse bone marrow-derived persisting cells (P-cells) primed with interleukin-3-containing conditioned medium (IL3-CM). Gen Pharmacol. 1993 Sep;24(5):1207-11. PubMed PMID: 7505757. 14: Tanimukai T, Ihaku D, Matsuyama T. [Role of adhesion molecules (VLA-4) in the asthmatic response to allergens]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Nov;33(11):1240-9. Japanese. PubMed PMID: 8583716.